Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Clinipace Worldwide Acquires Switzerland-Based PFC Pharma Focus Ltd.

By Pharmaceutical Processing | May 18, 2011

 

Clinipace Worldwide, a global digital clinical research organization
(dCRO), and Swiss-based PFC Pharma Focus (PFC) today jointly announced a
definitive merger agreement under which Clinipace Worldwide has acquired all
outstanding shares of privately-held PFC and its subsidiaries. Based in Zurich, Switzerland
– with offices in Germany, Israel and India – PFC is a pan-European contract
research provider focused on drug and medical device development services and regulatory
consulting.

The combination of PFC and Clinipace Worldwide creates a
truly global dCRO with centralized North American, South American, and European
hubs for strategic drug and medical device product development, clinical
operations, data management, regulatory affairs, and GxP/CMC quality assurance.
The companies share a collective vision of helping emerging and mid-tier life
science firms clients serve patients by substantially accelerating the drug and
device development processes via technology-amplified services. Clinipace is
strongly differentiated in the marketplace through its proprietary technology -based
dCRO value proposition which gives clients more control over timelines and
resources, enhanced project visibility, reduced cost, and improved risk
mitigation.

“With this acquisition, our third in the past 18
months, we have assembled the right global footprint and the right mix of
global therapeutic expertise, strategic product development assets and operational
capabilities to uniquely meet the needs of our clients,” commented Jeff
Williams, CEO and Chairman, Clinipace Worldwide.

“Together with the PFC team we’re better positioned to
serve the needs of our clients by quickly and efficiently scaling to support
their global phase 2-3 trials across a number of therapeutic areas and indications.”
“This is a great win for our client base as they now have access to Clinipace’s
extensive experience and capabilities in conducting trials and providing
regulatory consulting across North and South America;
as well as their proven technology (TEMPO(TM) eClinical platform),” said Kurt
Pfister, CEO, European Operations, Clinipace Worldwide (former CEO, PFC Pharma
Focus, Ltd.)   

Related Articles Read More >

These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
Thermo Fisher Scientific
Thermo Fisher to invest $2B on U.S. manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE